Wednesday, October 22, 2014

What Is Breast Cancer?

“Just think about the many things that might cause the wear and tear that leads to abnormal cell growth—pollutants, hormones, pesticides, smoking, alcohol use, obesity, stress…. Or maybe your cells just made a mistake one day when they were making new genes to pass on to their baby cells. Perhaps there was a misprint in the genetic instruction manual that said switch growth on instead of growth off. This is a test. ”
Breast cancer is an uncontrolled growth of breast cells. To better understand breast cancer, it helps to understand how any cancer can develop.
Cancer occurs as a result of mutations, or abnormal changes, in the genes responsible for regulating the growth of cells and keeping them healthy. The genes are in each cell’s nucleus, which acts as the “control room” of each cell. Normally, the cells in our bodies replace themselves through an orderly process of cell growth: healthy new cells take over as old ones die out. But over time, mutations can “turn on” certain genes and “turn off” others in a cell. That changed cell gains the ability to keep dividing without control or order, producing more cells just like it and forming a tumor.
A tumor can be benign (not dangerous to health) or malignant (has the potential to be dangerous). Benign tumors are not considered cancerous: their cells are close to normal in appearance, they grow slowly, and they do not invade nearby tissues or spread to other parts of the body. Malignant tumors are cancerous. Left unchecked, malignant cells eventually can spread beyond the original tumor to other parts of the body.
The term “breast cancer” refers to a malignant tumor that has developed from cells in the breast. Usually breast cancer either begins in the cells of the lobules, which are the milk-producing glands, or the ducts, the passages that drain milk from the lobules to the nipple. Less commonly, breast cancer can begin in the stromal tissues, which include the fatty and fibrous connective tissues of the breast.
Breast AnatomyBreast Anatomy
Over time, cancer cells can invade nearby healthy breast tissue and make their way into the underarm lymph nodes, small organs that filter out foreign substances in the body. If cancer cells get into the lymph nodes, they then have a pathway into other parts of the body. The breast cancer’s stage refers to how far the cancer cells have spread beyond the original tumor
Breast cancer is always caused by a genetic abnormality (a “mistake” in the genetic material). However, only 5-10% of cancers are due to an abnormality inherited from your mother or father. About 90% of breast cancers are due to genetic abnormalities that happen as a result of the aging process and the “wear and tear” of life in general.
While there are steps every person can take to help the body stay as healthy as possible (such as eating a balanced diet, not smoking, limiting alcohol, and exercising regularly), breast cancer is never anyone's fault. Feeling guilty, or telling yourself that breast cancer happened because of something you or anyone else did, is not productive.


Sunday, May 8, 2011

Harry Potter and the Deathly Hallows: Part 2

Director: David Yates
Writers: Steve Kloves (screenplay), J.K. Rowling (novel)
Stars: Daniel Radcliffe, Emma Watson and Rupert Grint
The end begins as Harry, Ron, and Hermione go back to Hogwarts to find and destroy Voldemort's final horcruxes, but when Voldemort finds out about their mission, the biggest battle begins and life as they know it will never be the same again
Download movie here...

Wednesday, April 20, 2011

Nikita

Stars: Maggie Q, Shane West and Lyndsy Fonseca
The story centers on a secret organization known as Division. Targeting young people from a troubled background, Division erases all evidence of their past lives and molds them into efficient spies and assassins. Nikita is the first recruit to escape and promises to bring down her former employers. Having trained Nikita, Michael, a Division operative, is ordered by his boss Percy to deal with his former student. In the meantime, Division continues training its recruits, Thom, Jaden, and the newest, Alex.
Download here

Friday, July 31, 2009

How is IBC knowledge spread?

What forms of communication do oncologists use to spread the word about inflammatory breast cancer?
Publications, and presentations at national and regional meetings.

Specialists in inflammatory breast cancer?

Is there a database of oncologists and surgeons that specialize in IBC?
I don't believe there is. Major cancer centers with strong inter-disciplinary teams would have the necessary expertise, but there is no list that I am aware of.

Look for treatment near home, or travel?

IBC diagnosed 2 days ago. Trying to decide if it's better to travel 2 hours alone to a major cancer center or stay with my support and go to a local cancer center in our area. How important is the psychological support versus a cutting-edge hospital?
For high-risk and aggressive breast cancers, including inflammatory breast cancer, one usually has a single opportunity for cure. It is critical to find a well-trained and highly interactive team of breast cancer specialists in order to succeed. So especially for inflammatory breast cancer, it would be important to make the extra effort to find such a team. If such a team exists in your local community, then great. If it does not, the 2-hour trip is more than worth it.

Treatment for ulcerating skin metastases?

What treatment is suggested for ulcerating skin metastases?
Radiation tends to be effective at helping ulcerations heal and helps frequently with pain associated with ulceration.Depending on the timing of these ulcerated lesions in the overall treatment history, as well as the number and location of these lesions, one might select different treatments or treatment combinations. In the presence of a single or limited number of closely clustered ulcerated lesions, radiation might be an excellent choice. If there are multiple, especially widely spread lesions, then systemic therapy alone or in combination with selected local treatments might be a good choice too. Systemic treatments might be chemotherapy or hormonal therapy or something like Herceptin, depending on the type of tumor.

Thursday, July 30, 2009

IBC Research Foundation's BioBank beneficial?

Are you aware of the Inflammatory Breast Cancer Research Foundation's BioBank and do you feel this will be beneficial in the research we need?
For further understanding of the biology of inflammatory breast cancer, it is critical to develop collections of tumors and a well-annotated description of the patients and the treatment used for the treatment of that tumor. The more these selections of well-annotated tumors can be developed, the more rapidly we will learn how to best treat, monitor, and prevent these tumors.

Other options for professional opinion?

Could you advise whether M.D. Anderson would give second opinions via telephone/email for overseas patients with their new IBC clinic?
The management of M.D. Anderson is very complex and dependent on a closely coordinated team effort. The diagnosis and work-up and treatment decisions also depend on the ability to take a careful history and examine the patient. For these reasons, telephone and email consultations have the risk of providing individual patients less than optimal information. Accordingly, it is not M.D. Anderson's policy to offer such second opinions via email.

Taxol vs. Abraxane in recurrent IBC?

Can you comment on the use of Taxol vs. Abraxane in the treatment of recurrence in IBC, especially for the triple-negative cases?
Abraxane (chemical name: albumin-bound paclitaxel) is a new formulation of paclitaxel, which is the active component of Taxol. There is a single head-to-head comparison of Abraxane and Taxol which suggests that we can give higher doses of Abraxane and that Abraxane is slightly more effective at those higher doses than a standard dose of Taxol. Whether this applies to inflammatory breast cancer or not is unknown. But clearly Abraxane is an effective drug, although whether the cost differential is justified in the case of an individual patient should be discussed with the treating oncologist.

Post-treatment testing for recurrence?

What is the normal testing post-treatment to check for recurrence?
For most breast cancers, the follow-up is based on history and physical examination about ever 4-5 months after diagnosis, then every 3-6 months for the next 3 years or so, and yearly thereafter. In addition, one should do a mammogram of the remaining breast tissue once a year. For inflammatory breast cancer, probably the only consideration is that recurrences tend to happen early, within the first 2 years or so, and because it is a more aggressive disease, one might want to consider more frequent visits for examinations. But there is no need for imaging of the brain, liver, or lungs at this point.

High-dose chemo and IBC?

What's your opinion on high-dose chemotherapy for use with IBC?
High dose-chemotherapy remains a treatment under investigation for any and all types of breast cancer. It is not part of standard treatment. Whether it will have or whether it would have had effects in patients with inflammatory breast cancer remains to be determined, and unfortunately because there is such a small number of inflammatory breast cancers, there will never be a definitive trial of that question.

Wednesday, July 29, 2009

Repeat chemo for IBC recurrence okay?

Can chemotherapy for IBC be repeated when there is evidence of recurrence after one year? The first round of chemo was well tolerated, surgery and radiation also performed?
In general terms, when recurrence is detected within about 6 months or less from the last dose of a specific type of chemotherapy, then that same chemotherapy would not be the first choice for treating the recurrence because the time is so short that one would assume the tumor was resistant to that type of chemotherapy and one would select a chemotherapy drug that was not included in that first treatment. Fortunately for the breast cancer patients, there are multiple types of chemotherapy that are effective in managing breast cancer, including recurrent inflammatory breast cancer. Lapatinib, or Tykerb, was recently tested in a clinical trial specifically in patients with recurrent inflammatory breast cancer, and Tykerb was shown to have anti-tumor effects in about 1 in 3 patients if they had the HER2 abnormality.

How does IBC act when metastasized?

You didn't answer Kat's question re: does the IBC behave the same way in other parts of the body as it did in the primary site? We are not asking about likelihood of recurrence as much as what happens [and] how quickly in a secondary site?
First of all, I think we need to dispel the idea that inflammatory breast cancer looks like inflammation under the microscope. It does not. In terms of the question specifically, once inflammatory breast cancer spreads to other organs, it tends to behave much like other rapidly growing or aggressive breast cancer. Now because it is an aggressive form of breast cancer, it has a pattern of spread that is somewhat different from other forms of breast cancer. It tends to spread more often to the lungs, the brain, and the liver although certainly not exclusively so. Once it spreads, it is an aggressive tumor and tends to grow more rapidly and spread more rapidly than other forms of breast cancer like the hormone dependent non-inflammatory breast cancer.

Twice-a-day radiation more effective with IBC?

Have there been studies that show that twice-a-day radiation is more effective with IBC? Should it be standard protocol for IBC?
At M.D. Anderson, for many years we've been investigating whether giving radiation twice a day instead of once a day leads to an improved outcome. The information we have from our own institutional experience leads us to be optimistic about this approach. The theory behind giving twice-a-day radiation is that you can complete the treatment in a shorter period of time and therefore have less of a chance of the IBC tumor cells growing during the course of treatment. The treatments, however, have some side effects and risks that also need to be considered. In addition, this approach hasn't been thoroughly studied in a big head-to-head comparative trial, in part because IBC is a rare disease. I would hate to say that giving once-a-day radiation is wrong. It remains the most common radiation delivery schedule given in the United States. I do think it is reasonable to consider twice-a-day radiation, given the good results that have been reported by investigators at M.D. Anderson.

Double mastectomy for IBC?

Is the presence of IBC in one breast enough justification for the doctor to remove the other breast?
Removal of the other breast does not in any way improve the cure rate for patients with inflammatory breast cancer. Therefore it's not a standard part of treatment.

Risk of IBC recurrence?

Since IBC is an aggressive form of breast cancer, if it should spread to other areas of the body, does it act the same way there—for example, fast growing? I was diagnosed with it December 2003, completed treatment August 2004 and have had no evidence of disease since?
Kat, I'm happy to hear you're doing well after completion of your treatment. It is true that if IBC were to recur, it tends to reoccur earlier compared to non-IBC breast cancer. For example, non-IBC breast cancer can even recur a decade after treatment. This would be very, very unusual for patients with IBC. I hope yours will never recur.

Tuesday, July 28, 2009

Gene therapy for IBC?

What kinds of gene therapy are being looked at for IBC ?
I'm not aware of a gene therapy trial for inflammatory breast cancer. There are ongoing trials for breast cancer in general, but all of them are in the very early stages of development, mostly Phase 1 trial. But nothing specifically for inflammatory breast cancer. When new drugs are developed, the very first step is to establish what is the best way to give the drug, how much should be given, how frequently, and how well patients tolerate that way of administering the drug. The same is true for gene therapy, for gene therapy is, in a way, a drug. So at this stage in the gene therapy trial, they are trying to determine the best way to administer the gene therapy, how frequently, and how much needs to be administered to get the predicted effect. Only later in the second stage do those clinical trials get to be reliable enough so that one knows that the drug or gene therapy is given the best way so one can expect the best possible results. At this point, gene therapy is not considered part of standard treatment of inflammatory breast cancer.

Clinical trials for IBC with brain metastases?

Are there any clinical trials available at M.D. Anderson Cancer Center that would benefit an IBC patient who has received treatment as you've outlined yet now has evidence of recurrence in the chest and brain metastases? Now evidently a stage IV patient?
In general terms, most clinical trials unfortunately do not include patients with brain metastases, mostly because of safety concerns. So at this point, and without looking at my priority list, I can't think of a specific clinical trial for patients with inflammatory breast cancer and brain metastases. We might have a clinical trial of new drugs for patients with metastatic brain cancer and brain metastases, and whether a particular patient could be a candidate would require a more in-depth assessment for all the relevant information. The right person to call for this would be Dr. Stacy Moulder at 713-792-2817, or Dr. Massimo Cristofanilli at the same number.

Clinical trials for IBC with brain metastases?

I am the minority with IBC that was also HER2, ER and PR positive. I have completed combination chemo, mastectomy, radiation, Herceptin and am now on Femara. Do you think Femara treatment will be extended beyond the 5-year plan?
That's a crystal ball question. I think we could say that there are ongoing clinical trials to determine whether prolonging the duration of Femara or similar drugs beyond 5 years is useful and well tolerated. The results of those trials will become available probably in the next 3-5 years.